Long-Term Survival Following Minimally Invasive Lung Cancer Surgery: Comparing Robotic-Assisted and Video-Assisted Surgery.
RATS
VATS
disease-free survival
long-term survival
minimally invasive surgery
non-small cell lung cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 May 2022
25 May 2022
Historique:
received:
14
04
2022
revised:
12
05
2022
accepted:
18
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Nowadays, video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS) are known to be safe and efficient surgical procedures to treat early-stage non-small cell lung cancer (NSCLC). We assessed whether RATS increased disease-free survival (DFS) compared with VATS for lobectomy and segmentectomy. This retrospective cohort study included patients treated for resectable NSCLC performed by RATS or VATS, in our tertiary care center from 2012 to 2019. Patients' data were prospectively recorded and reviewed in the French EPITHOR database. Primary outcomes were 5-year DFS for lobectomy and 3-year DFS for segmentectomy, compared by propensity-score adjusted difference of Kaplan-Meier estimates. Among 844 lung resections, 436 VATS and 234 RATS lobectomies and 46 VATS and 128 RATS segmentectomies were performed. For lobectomy, the adjusted 5-year DFS was 60.9% (95% confidence interval (CI) 52.9-68.8%) for VATS and 52.7% (95%CI 41.7-63.7%) for RATS, with a difference estimated at -8.3% (-22.2-+4.9%, RATS failed to show its superiority over VATS for resectable NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Nowadays, video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS) are known to be safe and efficient surgical procedures to treat early-stage non-small cell lung cancer (NSCLC). We assessed whether RATS increased disease-free survival (DFS) compared with VATS for lobectomy and segmentectomy.
METHODS
METHODS
This retrospective cohort study included patients treated for resectable NSCLC performed by RATS or VATS, in our tertiary care center from 2012 to 2019. Patients' data were prospectively recorded and reviewed in the French EPITHOR database. Primary outcomes were 5-year DFS for lobectomy and 3-year DFS for segmentectomy, compared by propensity-score adjusted difference of Kaplan-Meier estimates.
RESULTS
RESULTS
Among 844 lung resections, 436 VATS and 234 RATS lobectomies and 46 VATS and 128 RATS segmentectomies were performed. For lobectomy, the adjusted 5-year DFS was 60.9% (95% confidence interval (CI) 52.9-68.8%) for VATS and 52.7% (95%CI 41.7-63.7%) for RATS, with a difference estimated at -8.3% (-22.2-+4.9%,
CONCLUSIONS
CONCLUSIONS
RATS failed to show its superiority over VATS for resectable NSCLC.
Identifiants
pubmed: 35681593
pii: cancers14112611
doi: 10.3390/cancers14112611
pmc: PMC9179652
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Thorac Cardiovasc Surg. 2018 Feb;155(2):778-786
pubmed: 29031947
Innovations (Phila). 2019 Apr;14(2):90-116
pubmed: 31039680
World J Surg Oncol. 2017 May 8;15(1):98
pubmed: 28482928
J Thorac Oncol. 2016 Aug;11(8):1326-1334
pubmed: 27257134
BMJ Open. 2019 Oct 14;9(10):e029507
pubmed: 31615795
J Thorac Cardiovasc Surg. 2019 Sep;158(3):895-907
pubmed: 31078312
J Thorac Dis. 2019 Apr;11(4):1243-1250
pubmed: 31179066
Lancet Oncol. 2016 Jun;17(6):836-844
pubmed: 27160473
J Thorac Dis. 2018 Apr;10(Suppl 10):S1195-S1204
pubmed: 29785294
Ann Thorac Surg. 2013 Sep;96(3):943-9; discussion 949-50
pubmed: 23684159
Interact Cardiovasc Thorac Surg. 2022 Jun 1;34(6):1016-1023
pubmed: 34687546
J Thorac Cardiovasc Surg. 2010 Feb;139(2):366-78
pubmed: 20106398
Eur J Cardiothorac Surg. 2013 Apr;43(4):813-7
pubmed: 22826474
J Thorac Dis. 2016 Oct;8(Suppl 9):S738-S743
pubmed: 28066677
Chest. 2020 May;157(5):1313-1321
pubmed: 31589843
Rev Mal Respir. 2008 Oct;25(8):1031-6
pubmed: 18971809
J Thorac Oncol. 2019 Dec;14(12):2176-2180
pubmed: 31437532
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Ann Thorac Surg. 2020 Oct;110(4):1139-1146
pubmed: 32360876
Ann Surg. 2021 Sep 16;:
pubmed: 34534988
Cancers (Basel). 2021 Jul 23;13(15):
pubmed: 34359612
Eur J Cardiothorac Surg. 2016 Feb;49(2):602-9
pubmed: 25913824
Interact Cardiovasc Thorac Surg. 2017 Sep 1;25(3):469-475
pubmed: 28541531
Interact Cardiovasc Thorac Surg. 2020 Feb 1;30(2):255-262
pubmed: 31605110
Eur J Cardiothorac Surg. 2016 Mar;49(3):870-5
pubmed: 26088592
Eur J Cardiothorac Surg. 2019 Jan 1;55(1):91-115
pubmed: 30304509
Respiration. 2018;95(5):354-361
pubmed: 29393273
Stat Med. 2018 Jun 30;37(14):2252-2266
pubmed: 29682776
Ann Surg. 2019 Jan;269(1):163-171
pubmed: 28799982
Stat Med. 2016 Jul 20;35(16):2726-40
pubmed: 26891706
Eur J Cardiothorac Surg. 2021 Apr 29;59(4):732-740
pubmed: 33367615
Interact Cardiovasc Thorac Surg. 2019 Apr 1;28(4):526-534
pubmed: 30496420
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Eur J Cardiothorac Surg. 2019 Mar 1;55(3):427-433
pubmed: 30325403
Ann Oncol. 2014 Aug;25(8):1462-74
pubmed: 24562446
Am J Epidemiol. 2019 Jan 1;188(1):250-257
pubmed: 30189042
Ann Thorac Surg. 2016 Apr;101(4):1370-8
pubmed: 26872732
Surgery. 2021 Feb;169(2):436-446
pubmed: 33097244
Ann Surg. 2017 Feb;265(2):431-437
pubmed: 28059973
Ann Thorac Surg. 2014 Jan;97(1):236-42; discussion 242-4
pubmed: 24090577
Ann Cardiothorac Surg. 2012 May;1(1):70-6
pubmed: 23977470
Eur J Cardiothorac Surg. 2019 Feb 1;55(2):263-270
pubmed: 30052990
Ann Thorac Surg. 2014 Jun;97(6):1893-8; discussion 1899-900
pubmed: 24726600
Clin Lung Cancer. 2020 May;21(3):214-224.e2
pubmed: 31685354
BMJ. 2014 Oct 02;349:g5575
pubmed: 25277994
J Clin Oncol. 2018 Aug 10;36(23):2378-2385
pubmed: 29791289
J Thorac Dis. 2020 Jun;12(6):3369-3375
pubmed: 32642262
EJC Suppl. 2013 Sep;11(2):110-22
pubmed: 26217120
Ann Cardiothorac Surg. 2012 May;1(1):24-6
pubmed: 23977460
Front Oncol. 2021 Sep 09;11:726408
pubmed: 34568057
BMC Cancer. 2021 May 3;21(1):498
pubmed: 33941112